CC
KYTX icon

Caxton Corporation’s Kyverna Therapeutics KYTX Stock Holding History

Caxton Corporation’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$110K Sell
12,347
-6,426
-34% -$57K 5.94% 6
2026
Q1 		$162K Hold
18,773
– – 4.03% 3
2025
Q4 		$176K Sell
18,773
-4,208
-18% -$31.2K 4.12% 5
2025
Q3 		$138K Hold
22,981
– – 0.6% 8
2025
Q2 		$70.6K Hold
22,981
– – 0.72% 8
2025
Q1 		$44.4K Hold
22,981
– – 0.87% 8
2024
Q4 		$86K Hold
22,981
– – 0.52% 9
2024
Q3 		$112K Hold
22,981
– – 0.47% 9
2024
Q2 		$172K Buy
22,981
+7,135
+45% +$109K 0.87% 8
2024
Q1 		$394K Buy
+15,846
New +$442K 2.24% 5

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Caxton Corporation's KYTX Position: Q2 2026 in Review

Caxton Corporation reduced its Kyverna Therapeutics (KYTX) stake by 34% in Q2 2026, selling an estimated $57K and leaving 12,347 shares worth $110K. The position accounts for 5.94% of the portfolio, ranked #6.

Caxton Corporation first reported a position in KYTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $394K in Q1 2024. 121 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Caxton Corporation held 12,347 shares of Kyverna Therapeutics worth $110K as of Q2 2026.
  • Caxton Corporation sold 6,426 Kyverna Therapeutics shares in Q2 2026, an estimated $57K.
  • Kyverna Therapeutics made up 5.94% of Caxton Corporation's portfolio in Q2 2026, its #6 holding.
  • Caxton Corporation first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Caxton Corporation's Kyverna Therapeutics position peaked at $394K in Q1 2024.
  • 121 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Caxton Corporation's 13F filing for Q2 2026, filed 14 Aug 2026.